ARTICLE | Product Development
BioCentury’s Clinical Report also analyzes the impact of a patient death in Beam’s trial, plus data from Cogent, Disc, Essa and Novo
By Lauren Martz, Executive Director of Biopharma Intelligence, and Paul Bonanos, Director of Biopharma Intelligence
November 5, 2024 11:50 PM UTC


The TIGIT rollercoaster takes another turn, with overall survival data from a small study of Arcus’ domvanalimab that could swing sentiment in a positive direction, if slightly.
Arcus Biosciences Inc. (NYSE:RCUS) reported, ahead of a presentation at the Society for Immunotherapy of Cancer (SITC) conference this week, that domvanalimab plus PD-1 inhibitor zimberelimab reduced the risk of death by 36% when used as first-line therapy in patients with PD-L1-high non-small cell lung cancer (NSCLC) over zimberelimab alone…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/654087/arcus-data-the-latest-twist-in-the-tigit-story